Table 1.
Initial and decreased doses if dose-limiting toxicities are encountered for the 7 anatomic sites of metastases eligible for treatment on NRG-XXX (data partially appears in NRG-XXX: Table XXX).
| Prescription Doses | |||
|---|---|---|---|
| Metastatic Locations | Initial Starting Dose | BED per USC* | Decreased DLT Dose |
| Lung - Peripheral | 45 Gy (3 fractions) | 96 Gy | 42 Gy (3 fractions) |
| Lung - Central | 50 Gy (5 fractions) | 99 Gy | 47.5 Gy (3 fractions) |
| Mediastinal/Cervical lymph node | 50 Gy (5 fractions) | 99 Gy | 47.5 Gy (3 fractions) |
| Liver | 45 Gy (3 fractions) | 96 Gy | 42 Gy (3 fractions) |
| Spinal/Paraspinal | 30 Gy (3 fractions) | 60 Gy | 27 Gy (3 fractions) |
| Osseous | 30 Gy (3 fractions) | 60 Gy | 27 Gy (3 fractions) |
| Abdominal-pelvic metastases (lymph node/adrenal gland | 45 Gy (3 fractions) | 96 Gy | 42 Gy (3 fractions) |
*
Biological Effective Dose per the Universal Survival Curve, a measure of relative dose potency (13), assuming alpha = 0.33Gy−1, beta = 0.0385Gy−1, alpha/beta = 8.6, D0 = 1.25Gy